Literature DB >> 24238123

Sporadic nonfunctioning pancreatic neuroendocrine tumors: prognostic significance of incidental diagnosis.

David Jérémie Birnbaum1, Sébastien Gaujoux2, Rim Cherif1, Safi Dokmak1, David Fuks3, Anne Couvelard4, Marie-Pierre Vullierme5, Maxime Ronot6, Philippe Ruszniewski7, Jacques Belghiti3, Alain Sauvanet8.   

Abstract

BACKGROUND: Sporadic nonfunctioning pancreatic neuroendocrine tumors (NF-PNETs) are increasingly diagnosed as incidentalomas, and their resection is usually recommended. The prognostic significance of this diagnosis feature is poorly studied, and management of these tumors remains controversial. Clinical, pathologic characteristics and outcome of resected incidentally diagnosed NF-PNET (Inc) were compared with resected symptomatic NF-PNET (Symp) to better assess their biologic behavior and tailor their management.
METHODS: From 1994 to 2010, 108 patients underwent resection for sporadic nonmetastatic NF-PNET. Diagnosis was considered as incidental in patients with no abdominal symptoms or symptoms unlikely to be related to tumor mass. Patients with Inc were compared with patients with Symp, regarding demographics, postoperative course, pathology, and disease-free survival (DFS).
RESULTS: Of the 108 patients, 65 (61%) had incidentally diagnosed tumors. Pancreas-sparing pancreatectomies (enucleation/central pancreatectomy) were performed more frequently in Inc (62% vs 30%, P = .001). Inc tumors were more frequently <20 mm (65% vs 42%, P = .019), staged T1 (62% vs 33%, P = .0001), node negative (85% vs 60%; P = .005), and grade 1 (66% vs 33%, P = .0001). One postoperative death occurred in the Inc group, and postoperative morbidity was similar between the two groups (60% vs 65%, P = .59). DFS was substantially better in the Inc group (5-year DFS = 92% vs 82%, P = .0016).
CONCLUSION: Incidentally diagnosed NF-PNETs are associated with less aggressive features compared with symptomatic lesions but cannot always be considered to be benign. Operative resection remains recommended for most. Incidentally diagnosed NF-PNET may be good candidates for pancreas-sparing pancreatectomies.
Copyright © 2014 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 24238123     DOI: 10.1016/j.surg.2013.08.007

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  18 in total

Review 1.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

Review 2.  AACE/ACE disease state clinical review: pancreatic neuroendocrine incidentalomas.

Authors:  Miguel F Herrera; Göran Åkerström; Peter Angelos; Clive S Grant; Ana O Hoff; Juan Pablo Pantoja; Rocio Pérez-Johnston; Dushyant V Sahani; Richard J Wong; Gregory Randolph
Journal:  Endocr Pract       Date:  2015-05       Impact factor: 3.443

3.  Short- and long-term outcomes of laparoscopic organ-sparing resection in pancreatic neuroendocrine tumors: a single-center experience.

Authors:  Javier A Cienfuegos; Joseba Salguero; Jorge M Núñez-Córdoba; Miguel Ruiz-Canela; Alberto Benito; Sira Ocaña; Gabriel Zozaya; Pablo Martí-Cruchaga; Fernando Pardo; José Luis Hernández-Lizoáin; Fernando Rotellar
Journal:  Surg Endosc       Date:  2017-01-26       Impact factor: 4.584

Review 4.  Transabdominal ultrasonographic diagnosis of relatively rare pancreatic neoplasms.

Authors:  Senju Hashimoto; Kazunori Nakaoka; Hiroyuki Tanaka; Teiji Kuzuya; Naoto Kawabe; Mitsuo Nagasaka; Yoshihito Nakagawa; Ryoji Miyahara; Tomoyuki Shibata; Yoshiki Hirooka
Journal:  J Med Ultrason (2001)       Date:  2022-02-12       Impact factor: 1.314

5.  Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.

Authors:  Sara Krogh; Henning Grønbæk; Anders Riegels Knudsen; Peter Kissmeyer-Nielsen; Nynne Emilie Hummelshøj; Gitte Dam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

6.  ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors.

Authors:  M Falconi; B Eriksson; G Kaltsas; D K Bartsch; J Capdevila; M Caplin; B Kos-Kudla; D Kwekkeboom; G Rindi; G Klöppel; N Reed; R Kianmanesh; R T Jensen
Journal:  Neuroendocrinology       Date:  2016-01-05       Impact factor: 4.914

7.  A giant non-functioning pancreatic neuroendocrine carcinoma founded as an incidentaloma successfully treated with pancreatoduodenectomy.

Authors:  Jacek Paszkowski; Adam Bobkiewicz; Józef Świrkowicz; Łukasz Krokowicz; Jan Majewski; Tomasz Banasiewicz; Michał Drews
Journal:  Prz Gastroenterol       Date:  2016-08-05

8.  Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas.

Authors:  Young Jin Yoo; Seok Jeong Yang; Ho Kyoung Hwang; Chang Moo Kang; Hogeun Kim; Woo Jung Lee
Journal:  Medicine (Baltimore)       Date:  2015-09       Impact factor: 1.817

9.  Pancreatic solid incidentalomas.

Authors:  Erwin Santo; Iddo Bar-Yishay
Journal:  Endosc Ultrasound       Date:  2017-12       Impact factor: 5.628

10.  Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.

Authors:  Logan Mills; Panagiotis Drymousis; Yogesh Vashist; Christoph Burdelski; Andreas Prachalias; Parthi Srinivasan; Krishna Menon; Corina Cotoi; Saboor Khan; Judith Cave; Thomas Armstrong; Martin O Weickert; Jakob Izbicki; Joerg Schrader; Andreja Frilling; John K Ramage; Raj Srirajaskanthan
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.